Linked Life Data

21111777

Source:http://linkedlifedata.com/resource/pubmed/id/21111777

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2011-1-24
pubmed:abstractText
Venezuelan equine encephalitis virus replicon particles (VRP) without a transgene (null VRP) have been used to adjuvant effective humoral [1], cellular [2], and mucosal [3] immune responses in mice. To assess the adjuvant activity of null VRP in the context of a licensed inactivated influenza virus vaccine, rhesus monkeys were immunized with Fluzone(®) alone or Fluzone(®) mixed with null VRP and then challenged with a human seasonal influenza isolate, A/Memphis/7/2001 (H1N1). Compared to Fluzone(®) alone, Fluzone(®)+null VRP immunized animals had stronger influenza-specific CD4(+) T cell responses (4.4 fold) with significantly higher levels of virus-specific IFN-? (7.6 fold) and IL-2 (5.3 fold) producing CD4+ T cells. Fluzone(®)+null VRP immunized animals also had significantly higher plasma anti-influenza IgG (p<0.0001, 1.3 log) and IgA (p<0.05, 1.2 log) levels. In fact, the mean plasma anti-influenza IgG titers after one Fluzone(®)+null VRP immunization was 1.2 log greater (p<0.04) than after two immunizations with Fluzone(®) alone. After virus challenge, only Fluzone(®)+null VRP immunized monkeys had a significantly lower level of viral replication (p<0.001) relative to the unimmunized control animals. Although little anti-influenza antibody was detected in the respiratory secretions after immunization, strong anamnestic anti-influenza IgG and IgA responses were present in secretions of the Fluzone(®)+null VRP immunized monkeys immediately after challenge. There were significant inverse correlations between influenza RNA levels in tracheal lavages and plasma anti-influenza HI and IgG anti-influenza antibody titers prior to challenge. These results demonstrate that null VRP dramatically improve both the immunogenicity and protection elicited by a licensed inactivated influenza vaccine.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1873-2518
pubmed:author
pubmed:copyrightInfo
Copyright © 2010 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:day
29
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
931-40
pubmed:dateRevised
2011-10-6
pubmed:meshHeading
pubmed-meshheading:21111777-Adjuvants, Immunologic, pubmed-meshheading:21111777-Animals, pubmed-meshheading:21111777-Antibodies, Viral, pubmed-meshheading:21111777-CD4-Positive T-Lymphocytes, pubmed-meshheading:21111777-Disease Models, Animal, pubmed-meshheading:21111777-Drug Carriers, pubmed-meshheading:21111777-Encephalitis Virus, Venezuelan Equine, pubmed-meshheading:21111777-Female, pubmed-meshheading:21111777-Genetic Vectors, pubmed-meshheading:21111777-Hemagglutination Inhibition Tests, pubmed-meshheading:21111777-Immunoglobulin A, pubmed-meshheading:21111777-Immunoglobulin G, pubmed-meshheading:21111777-Influenza A Virus, H1N1 Subtype, pubmed-meshheading:21111777-Influenza Vaccines, pubmed-meshheading:21111777-Interferon-gamma, pubmed-meshheading:21111777-Interleukin-2, pubmed-meshheading:21111777-Macaca mulatta, pubmed-meshheading:21111777-Male, pubmed-meshheading:21111777-Mice, pubmed-meshheading:21111777-Orthomyxoviridae Infections, pubmed-meshheading:21111777-Primate Diseases, pubmed-meshheading:21111777-Trachea, pubmed-meshheading:21111777-Vaccines, Inactivated
pubmed:year
2011
pubmed:articleTitle
Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone ® in rhesus macaques.
pubmed:affiliation
Center for Comparative Medicine, University of California-Davis, One Shields Avenue, Davis, CA 95616, USA. tdcarroll@ucdavis.edu
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural